Cooley Guides Gilead Sciences to High Stakes Victory

Palo Alto – August 26, 2014 – Cooley LLP announced today that it scored a significant victory for client Gilead Sciences in an arbitration initiated by Hoffmann-La Roche (Roche) over rights to Gilead's blockbuster hepatitis C drug, Sovaldi (sofosbuvir).

Following a two-week arbitration hearing, a panel of three arbitrators issued its award on August 15, 2014, ruling in favor of Gilead and finding that Roche failed to establish any of its claims. As a result, Roche is not entitled to any damages or other relief. The opinion remains confidential at this time.

Sovaldi is a revolutionary new therapy for individuals infected with the hepatitis C virus. It was approved by the FDA as a breakthrough drug in December 2013. The drug cures more than 90 percent of patients with the most common form of hepatitis C, and it enables patients to avoid the need for more costly treatments, such as liver transplants. Thus far, Sovaldi has been one of the most successful drug launches of all time, with sales reaching $5.75 billion through the first six months of 2014. 

The core team representing Gilead was comprised of Cooley's chairman, Steve Neal, fellow partners Marty Schenker, Michelle Rhyu and Jeffrey Karr, and associates Scott Sukenick, Susan Krumplitsch, Daniel Knauss, Angela Purcell, Jeff Walker, Jennifer Lerner, Lauren Pomeroy and David Houska.

Steve Neal was recently recognized in The American Lawyer's "Litigator of the Week" series for spearheading the win.

About Cooley LLP

Cooley's attorneys solve legal issues for entrepreneurs, investors, financial institutions and established companies. Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and bet-the-company litigation, often where innovation meets the law.

Cooley has more than 750 lawyers across 11 offices in the United States and China.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.